Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.
Roche aims to defend the company’s multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of the Swiss drugmaker’s $4 billion-per-year Ocrevus product and advanced trials of the experimental medicine fenebrutinib.
Shares of Akcea Therapeutics were up more than 60 percent in trading after majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24 percent of available stock for $18.50 per share.
South San Francisco-based Unity Biotechnology reported that the 12-week results from the company’s Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
With a $425 million upfront payment, Bayer bolstered the company’s women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and an investigational treatment for menopause.
Cambridge, Massachusetts-based Praxis Precision Medicines raised about $110 million in a Series C financing, led by Eventide Asset Management,
Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments.
Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.
Sanofi Genzyme Executive VP Bill Sibold spoke to BioSpace about the company’s core pipeline focus, programs aimed at COVID-19, and what the future of the industry and patient care could look like in a post-COVID-19 world.
CSL Behring bolstered the company’s growing gene therapy portfolio with the acquisition of global rights to uniQure’s gene therapy program for hemophilia B that has a price tag of up to $2 billion.
